Cost implications of antimuscarinic drugs in the treatment of overactive bladder syndrome

Author： Perimenis Petros   Konstantinopoulos Angelis   Giannitsas Konstantinos   Athanasopoulos Anastasios  

Publisher： Informa Healthcare

ISSN： 1465-6566

Source： Expert Opinion on Pharmacotherapy, Vol.7, Iss.5, 2006-04, pp. : 539-544

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Pharmacokinetics and toxicity of antimuscarinic drugs for overactive bladder treatment in females

By Leone Roberti Maggiore Umberto   Salvatore Stefano   Alessandri Franco   Remorgida Valentino   Origoni Massimo   Candiani Massimo   Venturini Pier Luigi   Ferrero Simone  

Expert Opinion on Drug Metabolism and Toxicology, Vol. 8, Iss. 11, 2012-11 ,pp. : 1387-1408

Informa Healthcare

Access to resources Recommend Favorite

Antimuscarinic Treatment in Overactive Bladder: Special Considerations in Elderly Patients

By Wagg Adrian S.  

Drugs & Aging, Vol. 29, Iss. 7, 2012-07 ,pp. : 539-548

Adis International

Access to resources Recommend Favorite

Cardiovascular effects of antimuscarinic agents in overactive bladder

By Rosa Gian Marco   Bauckneht Matteo   Scala Carolina   Tafi Emanuela   Leone Roberti Maggiore Umberto   Ferrero Simone   Brunelli Claudio  

Expert Opinion on Drug Safety, Vol. 12, Iss. 6, 2013-11 ,pp. : 815-827

Informa Healthcare

Access to resources Recommend Favorite

Solifenacin in Overactive Bladder Syndrome

By Payne Christopher K.  

Drugs, Vol. 66, Iss. 2, 2006-01 ,pp. : 175-190

Adis International

Access to resources Recommend Favorite

Solifenacin in Overactive Bladder Syndrome

By Simpson Dene   Wagstaff Antona J.  

Drugs & Aging, Vol. 22, Iss. 12, 2005-01 ,pp. : 1061-1069

Adis International

Access to resources Recommend Favorite